ReviewInternational journal of molecular sciences2013
Towards a molecular understanding of the biosynthesis of amaryllidaceae alkaloids in support of their expanding medical use.
Review in International journal of molecular sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 105 citations in OpenAlex.
- From Explant Selection to Bioreactor Cultivation: Development of aPlants (Basel, Switzerland) · 2026Article
- Elucidating the enzyme network driving Amaryllidaceae alkaloids biosynthesis in Leucojum aestivum.Plant biotechnology journal · 2025Article
- Naturally-occurring nematicides of plant origin: two decades of novel chemistries.Pest management science · 2025Review
- Medicinal compounds and biotechnology of Amaryllidaceae alkaloids inFrontiers in plant science · 2025Review
- Navigating Amaryllidaceae alkaloids: bridging gaps and charting biosynthetic territories.Journal of experimental botany · 2025Review
- Review
- The Anti-Cholinesterase Potential of Fifteen Different Species ofLife (Basel, Switzerland) · 2024Article
- Combination of Probe Electrospray Ionization Mass Spectrometry and Mass Spectrometry Imaging to Analyze Plant Alkaloids inMass spectrometry (Tokyo, Japan) · 2024Article
- Anti-SARS-CoV-2 Activity and Cytotoxicity of Amaryllidaceae Alkaloids fromMolecules (Basel, Switzerland) · 2023Article
- The Phytochemistry and Pharmacology ofMolecules (Basel, Switzerland) · 2022Review
- Biotechnological Approaches to Optimize the Production of Amaryllidaceae Alkaloids.Biomolecules · 2022Review
- Amaryllidaceae plants: a potential natural resource for the treatment of Chagas disease.Parasites & vectors · 2021Article
- The snowdrop, wellspring of galanthamine : A brief descriptive and scientific history.Wiener medizinische Wochenschrift (1946) · 2021Article
- Galantamine Quantity and Alkaloid Profile in the Bulbs ofMetabolites · 2021Article
- Biosynthesis and Biological Activities of Newly Discovered Amaryllidaceae Alkaloids.Molecules (Basel, Switzerland) · 2020Review
- Recent Progress in Amaryllidaceae Biotechnology.Molecules (Basel, Switzerland) · 2020Review
- Application of in vivo solid phase microextraction (SPME) in capturing metabolome of apple (Malus ×domestica Borkh.) fruit.Scientific reports · 2020Article
- Transcriptome Analysis of Different Tissues Reveals Key Genes Associated With Galanthamine Biosynthesis inFrontiers in plant science · 2020Article
- Macrophylloflavone: A New Biflavonoid fromTheScientificWorldJournal · 2020Article
- The GenusMolecules (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The alkaloids characteristically produced by the subfamily Amaryllidoideae of the Amaryllidaceae, bulbous plant species that include well know genera such as Narcissus (daffodils) and Galanthus (snowdrops), are a source of new pharmaceutical compounds. Presently, only the Amaryllidaceae alkaloid galanthamine, an acetylcholinesterase inhibitor used to treat symptoms of Alzheimer's disease, is produced commercially as a drug from cultivated plants. However, several Amaryllidaceae alkaloids have shown great promise as anti-cancer drugs, but their further clinical development is restricted by their limited commercial availability. Amaryllidaceae species have a long history of cultivation and breeding as ornamental bulbs, and phytochemical research has focussed on the diversity in alkaloid content and composition. In contrast to the available pharmacological and phytochemical data, ecological, physiological and molecular aspects of the Amaryllidaceae and their alkaloids are much less explored and the identity of the alkaloid biosynthetic genes is presently unknown. An improved molecular understanding of Amaryllidaceae alkaloid biosynthesis would greatly benefit the rational design of breeding programs to produce cultivars optimised for the production of pharmaceutical compounds and enable biotechnology based approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.